Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Sistema de Diagnóstico y Monitoreo Basado en Biomarcadores Urinarios para la Enfermedad Renal Crónica y Efectividad en el Mundo Real de los Inhibidores de SGLT2

4 de noviembre de 2026 actualizado por: Instituto de Investigación Biomédica de Salamanca

Sistema de Diagnóstico y Monitoreo para la Enfermedad Renal Crónica Basado en Biomarcadores Urinarios y Tratamiento Preventivo con el Inhibidor del SGLT2 Empagliflozina

This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.

No investigational product is assigned, and medical practice or prescription patterns are not altered.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This is a real-world, observational study with prospective follow-up and retrospective baseline data when available, conducted at the Nephrology Department of the University Hospital of Salamanca, Spain.

The project integrates translational and clinical components:

  1. validation of a urinary biomarker panel obtained through differential proteomics for early detection and monitoring of CKD progression, and
  2. evaluation of the effectiveness and safety of SGLT2i in routine clinical practice.

A total of 300 adults with CKD stages 2-4 will be included (150 initiating SGLT2i and 150 matched controls). Participants will be followed for 12 months (baseline, 6, and 12 months). Data will be extracted exclusively from electronic health records and laboratory systems.

The primary outcome is the annual decline rate of estimated glomerular filtration rate (eGFR, CKD-EPI 2021). Secondary outcomes include a composite renal endpoint (≥40% sustained eGFR decline, renal replacement therapy, transplantation, or renal death), cardiovascular hospitalization, all-cause mortality, adverse drug reactions (ADRs), and real-world patterns of SGLT2i use.

Exploratory analyses will assess associations between urinary biomarkers and clinical outcomes.

The study follows Spanish regulations for observational studies with medicinal products (Real Decreto 957/2020), with ethics approval and informed consent for biological samples.

Tipo de estudio

De observación

Inscripción (Estimado)

300

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Carlos Martínez Salgado, PhD
  • Número de teléfono: +34616129633
  • Correo electrónico: carlosms@usal.es

Ubicaciones de estudio

      • Salamanca, España
        • Reclutamiento
        • Hospital Universitario de Salamanca
        • Contacto:
          • Carlos Martínez Salgado, PhD
          • Número de teléfono: +34616129633
          • Correo electrónico: carlosms@usal.es
        • Contacto:
          • Pilar Fraile Gómez, MD, PhD
          • Número de teléfono: +34923291100
          • Correo electrónico: pilarfg@usal.es

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

16 años y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

Participants with chronic kidney disease (CKD) stages 2-4.

Descripción

Inclusion Criteria:

  • ≥18 years old
  • Diagnosed with chronic kidney disease (KDIGO stages 2-4)
  • Life expectancy ≥12 months
  • Available clinical and laboratory data in the electronic medical record

Exclusion Criteria:

  • Current or recent renal replacement therapy or kidney transplantation
  • End-stage renal disease
  • Participation in interventional trials that may affect outcomes
  • Allergy or intolerance to SGLT2i (for exposed cohort)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Empagliflozin Treatment Group

Participants with chronic kidney disease (CKD) stages 2-4 will receive oral empagliflozin (10-25 mg daily) for 12 months. Urinary and plasma samples will be collected at baseline, 6 months, and 12 months to evaluate the urinary biomarker panel, renal function (eGFR), and treatment safety.

Oral empagliflozin (10-25 mg daily) for 12 months

Control group

Adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification) managed in nephrology outpatient clinics without initiation of SGLT2 inhibitors at baseline or during follow-up.

These patients receive standard clinical care according to local and national guidelines.

They are followed on the same schedule (baseline, 6, and 12 months) and have identical variables collected from electronic health records and laboratory systems.

Reasons for non-initiation of SGLT2i are documented systematically and may include:

Not meeting indication criteria established by the Spanish National Health System (e.g., albumin-to-creatinine ratio <200 mg/g, eGFR <20 mL/min/1.73 m² for empagliflozin or <25 for dapagliflozin), or

Clinical contraindications or conditions such as significant hypovolemia or hypotension, recurrent urinary or genital infections, or hypersensitivity.

Control patients will be censored in the primary analysis if they later start SGLT2i therapy (cross-over).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in urinary biomarker panel expression (proteomic fingerprint)
Periodo de tiempo: Baseline, 6 months, 12 months

Quantitative assessment of urinary biomarkers (including KIM-1, transferrin, IGFBP7, TIMP-2, among others) to evaluate disease progression and treatment response. Urinary biomarkers will be assessed using liquid chromatography-mass spectrometry (LC-MS/MS)-based differential proteomic analysis. Biomarker expression will be quantified as log2 fold change with false discovery rate (FDR) correction. Selected biomarkers will be validated using enzyme-linked immunosorbent assay (ELISA) or equivalent immunoassays. Biomarker concentrations will be normalized to urinary creatinine levels.

Baseline, 6 months, 12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in estimated glomerular filtration rate (eGFR)
Periodo de tiempo: Baseline, 6 months, 12 months

Evaluation of renal function improvement or stabilization during SGLT2 inhibitor treatment.

Baseline, 6 months, 12 months
Histopathological improvement of renal tissue (animal study)
Periodo de tiempo: Monthly up to 9 months

Monthly analysis of renal fibrosis, inflammation, and extracellular matrix accumulation in preclinical models treated with empagliflozin.

Monthly up to 9 months
Monitoring of adverse events of empagliflozin in CKD patients without diabetes
Periodo de tiempo: From baseline to 12 months

Adverse events (AEs) will be recorded and classified according to Common Terminology Criteria for Adverse Events (CTCAE, latest version), including severity grading and assessment of causality related to treatment.

Serious adverse events (SAEs) and discontinuations due to AEs will be specifically tracked by the investigator.

From baseline to 12 months
Change in estimated glomerular filtration rate (eGFR)
Periodo de tiempo: From baseline to 12 months

Change in renal function assessed by estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation during empagliflozin treatment using the Serum creatinine-based CKD-EPI equation.

From baseline to 12 months
Change in serum creatinine
Periodo de tiempo: From baselinte to 12 months

hange in serum creatinine levels to assess renal safety during treatment with empagliflozin by standard clinical laboratory assay (mg/dL).

From baselinte to 12 months
Change in urinary albumin-to-creatinine ratio
Periodo de tiempo: From baseline to 12 months

Change in urinary albumin-to-creatinine ratio as a marker of renal damage and safety during empagliflozin treatment by standard urine laboratory testing (mg/g creatinine).

From baseline to 12 months
Change in serum electrolyte levels
Periodo de tiempo: From baseline to 12 months

Change in serum sodium and potassium levels to evaluate electrolyte safety during empagliflozin treatment by standard clinical laboratory testing (mmol/L).

From baseline to 12 months
Change in liver function tests
Periodo de tiempo: From baseline to 12 months

Change in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to assess hepatic safety by standard clinical laboratory assays (U/L).

From baseline to 12 months
Change in glycated hemoglobin (HbA1c)
Periodo de tiempo: From baseline to 12 months.

Change in HbA1c levels to monitor metabolic safety in non-diabetic CKD patients treated with empagliflozin by standard laboratory assay (%).

From baseline to 12 months.
Change in hematological parameters
Periodo de tiempo: From baseline to 12 months

Change in complete blood count parameters to evaluate hematological safety during treatment by standard clinical laboratory testing.

From baseline to 12 months
Change in blood pressure
Periodo de tiempo: From baseline to 12 months

Assessment of changes in both blood pressures (systolic and diastolic), by Standard sphygmomanometer measurement (mmHg).

From baseline to 12 months
Change in body weight
Periodo de tiempo: From baseline to 12 months

Change in body weight to assess tolerability and volume status during empagliflozin treatment by calibrated clinical scale (kg).

From baseline to 12 months
Discontinuation due to treatment intolerance
Periodo de tiempo: From baseline to 12 months

Number and proportion of participants who permanently discontinue empagliflozin due to treatment-related intolerance or adverse events. It will be achieved trough clinical visit records and adverse event reporting.

From baseline to 12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Carlos Martínez Salgado, PhD, University of Salamanca
  • Investigador principal: Pilar Fraile Gómez, MD, PhD, University of Salamanca

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de abril de 2026

Finalización primaria (Estimado)

1 de abril de 2028

Finalización del estudio (Estimado)

1 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

18 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

12 de enero de 2026

Publicado por primera vez (Actual)

16 de enero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • PI25/00053

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.

Marco de tiempo para compartir IPD

Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.

Criterios de acceso compartido de IPD

Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .